Advanced Cell Technology Inc. of Marlborough says a third patient has been treated for Stargardt’s macular dystrophy in its US. Phase I/II clinical trial.
The therapy uses retinal pigment epithelial cells derived from human embryonic stem cells.
The third patient’s treatment completes the first cohort of patients for the trial. The company said it anticipates that the Data and Safety Monitoring Board, an independent advisory group, will review the patients’ results and safety data by early spring, potentially clearing the way for the treatment of a second cohort with a higher dosage of cells.
The most recent patient is the fifth worldwide to be treated with the RPE cells, and the company said there have been no complications or side effects so far.
